CYP2C9 is a major liver enzyme responsible of the metabolism of many clinically important drugs. The presence of CYP2C9 genetic polymorphisms has been associated with marked interindividual variability in its catalytic activity that could result in drug toxicity. Here we present frequencies of the most common CYP2C9 coding variants CYP2C9*2 (C430T) and CYP2C9*3 (A1075C) in representative samples of four regions from Spain (Basque Country, n ¼ 358; Catalonia, n ¼ 240; Central Spain, n ¼ 190 and Galicia, n ¼ 288) and one northern Italian region, (Verona, n ¼ 164), which range between 0.125 and 0.165 in the case of CYP2C9*2 and between 0.071 and 0.085 for CYP2C9*3. No significant differences between CYP2C9 allele frequencies were found comparing all the sampled populations. A more extensive comparative analysis using allele frequency data of populations widely spread over Europe was performed, showing significant differences in the CYP2C9*2 allele frequencies distribution between some of the regions, being quite homogeneous in the case of CYP2C9*3 variant. The results obtained show that above 40% of our samples carry a mutate allele, which can result in a poor metabolization of low therapeutic index drugs as oral anticoagulants (warfarin, acenocoumarol), oral antidiabetic drugs and some non-steroidal anti-inflammatory drugs. Our study constitutes both a large (n ¼ 1240) and robust allele frequency database on CYP2C9 polymorphisms, which represents one of the most numerous CYP2C9*2 and *3 database existing to date.
Introduction
Families 1-3 of the Cytochrome P450 enzymes play a critical role in the oxidative metabolism of the majority of clinically used drugs. These enzymes display polymorphism and their prevalence varies among different populations. [1] [2] [3] In particular, the polymorphic enzyme CYP2C9 is the most abundant of the CYP2C enzymes, 4 and it influences the metabolism of about 10-20% of therapeutically important drugs, 5 some with a narrow therapeutic index. A high number of genetic polymorphisms associated with wide interindividual variability in the hepatic metabolism of target drugs have been described in the regulatory and coding regions of CYP2C9 gene; 6 however, only two coding variants, CYP2C9*2 (C430T) and CYP2C9*3 (A1075C), with functional consequences are common. CYP2C9*2 codes for a R144C substitution and CYP2C9*3 reflects an I359L change in the amino-acid sequence. 7 It is thought that these variants are both associated with significant reductions in intrinsic clearance of a variety of CYP2C9 substrates compared with the wild type, which can result in an increase of dose-dependent adverse drug reactions. [8] [9] [10] For this reason, the knowledge of the prevalence of these CYP2C9 variants is of fundamental relevance for effective drug therapy especially to prevent the adverse response to therapeutic agents.
Currently, some studies on CYP2C9 polymorphisms have been published, but most of them analyse a limited number of individuals from major population groups or large geographic areas. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Here we present a descriptive study of the prevalence of the most relevant CYP2C9 polymorphisms, CYP2C9*1 (wild type), CYP2C9*2 and CYP2C9*3, in population samples from both Spain (Basque Country, Catalonia, Central Spain and Galicia) and northern Italy (Verona) summing up a total of 1240 individuals. We also compared the allele frequencies on our population samples with those previously published for other European populations. On the other hand, various single nucleotide polymorphisms (SNPs) were identified in the flanking region of the CYP2C9 gene, 23 which appear to influence CYP2C9 activity. However, the impact of these non-coding SNPs on CYP2C9 activity in vivo and in therapeutics still has to be evaluated in Caucasians. Furthermore, it is known that the genetic response could be related not only to individual SNPs but also to the combination of different SNPs in the same and other genes. So, we have analysed one of the most common 5 0 -flanking region polymorphisms: À1189C4T in the sample from Galicia, according to the methods described in Mas et al. 11 . Our results indicate that in future studies, CYP2C9 haplotypes could be better predictors of pharmacologic response associated to CYP2C9 metabolized drugs.
Results

Validation study
To validate the different methods used for genotyping, a set of 21 samples representing all different detected genotypes, and previously analysed by TaqMan system, were genotyped using single base extension (SBE) by SNaPshot according to Mas et al. 11 Concordance was 100% between both methods.
Allele, genotype and haplotype frequencies and Hardy-Weinberg equilibrium No significant deviations from Hardy-Weinberg expectations were observed in any of the studied populations on both variants (0.0576 oPo0.7921 on CYP2C9*2 and 0.3304 oPo1.000 on CYP2C9*3). Figure 1 illustrates the CYP2C9 allele frequencies observed in all the analysed populations. The genotype frequencies are summarized in Table 1 . In agreement to the published data obtained for other Caucasian populations (Table 2) , our results show that CYP2C9*2 allele is more common than CYP2C9*3 in all the samples. We observed that the most frequent genotype is the wild type (*1/*1) followed by the heterozygous for CYP2C9*2 and *3 alleles with an altered function, respectively ( Table 1 ).
The sample from Galicia was also typed for the 5 0 -flanking region polymorphism À1189C4T, and a frequency of 0.6 was obtained for the mutated allele, which was similar to that observed in related populations (B0.62 in Spaniards 11 ). We measured the linkage disequilibrium between pairs of SNPs and a very high value between 5 0 À1189C4T and C430T was obtained (D 0 ¼ 0.9) near to that estimated before by Morin et al. 16 On the contrary, the D 0 value between A1075C and both the others was lower (D 0 ¼ B0.5). Five different haplotypes including the three polymorphisms were inferred (Table 3) , bearing in mind that those with a frequency below 0.001 were omitted. We observed that the most frequent four haplotypes were those which were previously detected. 11, 16 No haplotype was determined by the combination of the three polymorphic sites.
Population diversity CYP2C9*2 and *3 allele frequencies were compared among the sampled populations and also among data previously published for 12 European populations scattered all over the continent from the United Kingdom, 17 Holland, 18 France, 16 Germany, 19 Hungary, 20 Italy, 21 Sweden, 22 Turkey, 12 Belgium, 13 Iran, 14 Spain 11 and the Europeans from the United States of America 23 (Table 4) . No significant differences were observed among our five samples in any of the CYP2C9 variants.
Although CYP2C9 allele frequency distributions seem to be quite uniform in European populations, looking at our samples, the CYP2C9*2 frequency comparisons show slightly significant differences in both Catalonia and Galicia versus the United Kingdom (0.0159 ± 0.0037 and 0.0197 ± 0.0041, respectively) and Turkey (0.03395 ± 0.0063 and 0.0318±0.0107, respectively), and between Galicia and Germany (0.0280±0.0063). Significant differences were also Figure 1 Frequency of the CYP2C9 *2 (a) and *3 (b) variants in the studied population samples.
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found between a sample from Italy and the United Kingdom (0.00965±0.0028), Germany (0.01840±0.0068), Sweden (0.01325 ± 0.0061) and Turkey (0.01485 ± 0.0039). In the CYP2C9*3 allele frequency comparisons no significant differences were obtained between our samples and all the collected populations (P40.05), being significant only between Turkey and the United Kingdom (0.00595±0.0030).
Furthermore, À1189C4T/C430T/A1075C haplotype frequency comparisons were performed between Galicia and population samples from France 16 and Spain 11 and no significant differences were observed (P40.05).
Discussion
In this large study, we report allele and genotype frequency data on CYP2C9*2 and *3 altered variants in five different regions from southern Europe. The obtained data show that, as we presumed, in all the sampled regions the frequency of CYP2C9*2 carriers is higher than the carriers of CYP2C9*3, the later having a stronger reduction of the catalytic activity of the enzyme with respect to the wild type. 10 The comparative analysis between our samples and other European populations shows that the frequency distribution of the CYP2C9*2 was slightly heterogeneous, as significant differences were obtained between some of the regions, being quite homogenous in the case of *3 allele.
The genotyping method based on a multiplex PCR and SBE reaction used in Galician sample covered two of the most important genetic variants that alter the CYP2C9 activity and also one SNP at position À1189C of the CYP2C9 promoter region. Using this method, samples could be processed in plates and the final genotypes could be obtained in a short period of time with a cost per genotype lower than that from convectional methods and other commercial assays. Thus, the SnaPshot-based genotyping proved to be robust, accurate, rapid and cost effective, and the results were easy to interpret, which is relevant to facilitate the application of pharmacogenetic data into clinical practice to improve personal drug therapy.
Due to the high linkage disequilibrium observed between the 5 0 -flanking region SNPs and the two coding CYP2C9 SNPs, C430T and A1075C, 24 these CYP2C9 haplotypes detected in the population from Galicia could become useful in pharmacogenetic studies as predictors of the interindividual variability in drug response, not explained just by the presence of the coding polymorphisms. This observation also suggests that the pharmacogenetic response associated to CYP2C9 substrates should be evaluated in future studies using more newly described CYP2C9 SNPs of interest. Resulting from grouping all the Spanish populations sampled for the study.
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Interethnic differences in frequencies of CYP2C9 variants might be responsible, at least in part, for the variation in drug disposition between main population groups. 3 Likewise, particular subpopulations with the same ethnicity could present differences in allele frequencies due to diverse causes. For that reason, it is really relevant to know the prevalence of CYP2C9 polymorphisms in different populations, even those coming from the same ethnic group. Thus, the precise assessment of the allele frequencies could help in future pharmacogenetic studies to optimize therapy with CYP2C9 substrates. However, a representative sample of the studied population, with a significant number of individuals and a clear definition of their origin, is required for the calculation of the allele frequencies.
Our study constitutes a large and robust allele frequency database on CYP2C9 polymorphisms, including representative samples of well-defined regions from northern Spain and Italy, making up one of the most numerous CYP2C9*2 and *3 databases. We observed that above 40% of individuals of our sample are altered metabolizers of the CYP2C9 substrates. This could be very relevant in the use of narrow therapeutic index drugs as oral anticoagulants (warfarin, acenocumarol), oral antidiabetic drugs and some nonsteroidal anti-inflammatory drugs (NSAIDs). Patients were selected as control group from a previous pharmacogenetic multicentre study regarding the genetic predisposition to gastrointestinal haemorrhage after NSAIDs use, in which the five sanitary centres have participated. After giving their informed consent, only adult residents in the sanitary area of the participant hospitals, without precedents of neoplasia, cirrhosis or coagulopathies, were included in the study. These individuals were selected to be representative of the population belonging to the sanitary area corresponding to each hospital. The study was approved by the ethical clinic committee of all the hospitals involved in the study.
Materials and methods
Subjects and samples
Each hospital used its own routine DNA extraction method.
Genotyping
Two different methods were used to genotype the variants of the CYP2C9 gene (CYP2C9*2 and CYP2C9*3). (1) The samples from Galicia were genotyped through a multiplex SBE method performed by SNaPshot technology (Applied Biosystems, Foster City, CA, USA), following the conditions described by Mas et al. 11 The first step consisted of a multiplex PCR which allows the amplification of the fragments including the variants C430T, A1075C and 5 0 -flanking region À1189C4T. Following that the purified PCR products are used in a multiplex SBE reaction where the detection primers 11 annealed adjacent to the SNP position. The allele detection was achieved using ABI 3130xl Genetic Analyzer (Applied Biosystems). The GeneMapper ID v3.2 software (Applied Biosystems) was used for the allele assignment. (2) In the remaining population samples, the CYP2C9 polymorphisms were detected by TaqMan Drug Metabolism Genotyping Assays (Applied Biosystems) in a 7900HT Real-Time PCR System (Applied Biosystems). The allele assignment was performed using the SDS 2.2.2 software (Applied Biosystems).
Statistical analysis
The SNPassoc R package version 2.7 25 was used for the estimation of allele and haplotype frequencies and for assessing the deviation from Hardy-Weinberg equilibrium in each population and SNP separately.
Haplotypes were inferred from the information about SNPs by the use of a phase reconstruction method 26 and the expectation-maximization algorithm in the Arlequin ver 3.1 package. 27 The linkage disequilibrium between each pair of SNPs (C430T, A1075C and 5 0 À1189C4T) was assessed using also the Arlequin ver 3.1 package 27 and expressed in terms of D 0 , only in the samples from Galicia. Population comparisons were performed by exact test of population differentiation implemented in the same software. 27 
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